Literature DB >> 12649204

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Denise C Connolly1, Rudi Bao, Alexander Yu Nikitin, Kasie C Stephens, Timothy W Poole, Xiang Hua, Skye S Harris, Barbara C Vanderhyden, Thomas C Hamilton.   

Abstract

In women, >80% of malignant ovarian tumors are of epithelial origin. Early detection of these tumors is very challenging,and extensive i.p. dissemination is common by the time of diagnosis. The lack of adequate geneticmouse models of ovarian carcinomas significantly delays advances in early detection and treatment. We report that female transgenic mice expressing the transforming region of SV40 under control of the Mullerian inhibitory substance type II receptor gene promoter develop bilateral ovarian tumors in approximately 50% of cases. Histologically, these tumors are poorly differentiated carcinomas with occasional cysts and papillary structures present at the surface of the ovary. These tumors disseminate i.p., invade omentum, and form ascites as do human ovarian carcinomas. The epithelial origin of these tumors is supported by detection of cytokeratins 8 and 19, and the absence of alpha-inhibin, a protein characteristically expressed in normal granulosa cells and most granulosa cell tumors. Cell lines derived from the ascites exhibit the properties of epithelial ovarian cancer, such as anchorage-independent growth, tumorigenicity in immunocompromised mice, expression of epithelial cell markers, and organotropic implantation. The availability of a transgenic mouse model of disseminated ovarian carcinoma and respective cell lines should advance our understanding of this neoplasm, and serve as a useful tool for the evaluation of emerging detection and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  136 in total

1.  Three-dimensional texture analysis of optical coherence tomography images of ovarian tissue.

Authors:  Travis W Sawyer; Swati Chandra; Photini F S Rice; Jennifer W Koevary; Jennifer K Barton
Journal:  Phys Med Biol       Date:  2018-12-04       Impact factor: 3.609

2.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

3.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

4.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

5.  Autoimmune mediated regulation of ovarian tumor growth.

Authors:  Cengiz Z Altuntas; Ritika Jaini; Pavani Kesaraju; Daniel Jane-wit; Justin M Johnson; Kelly Covey; Christopher A Flask; Martin Dutertre; Jean-Yves Picard; Vincent K Tuohy
Journal:  Gynecol Oncol       Date:  2011-10-18       Impact factor: 5.482

6.  In vitro three-dimensional modelling of human ovarian surface epithelial cells.

Authors:  K Lawrenson; E Benjamin; M Turmaine; I Jacobs; S Gayther; D Dafou
Journal:  Cell Prolif       Date:  2009-04-24       Impact factor: 6.831

7.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

8.  Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment.

Authors:  Jingfang Zheng; Imelda Mercado-Uribe; Daniel G Rosen; Bin Chang; Peishu Liu; Gong Yang; Anais Malpica; Honami Naora; Nelly Auersperg; Gordon B Mills; Robert C Bast; Jinsong Liu
Journal:  Cell Cycle       Date:  2010-01-05       Impact factor: 4.534

9.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Authors:  Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

10.  Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.

Authors:  Dallas B Flies; Tomoe Higuchi; Jaryse C Harris; Vibha Jha; Phyllis A Gimotty; Sarah F Adams
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.